Anticancer and apoptosis-inducing effects of Moringa concanensis using hepG2 cell lines
DOI:
https://doi.org/10.3329/bjp.v9i4.20481Keywords:
Anti-cancer, HepG-2 cell line, Moringa concanensis, MTT assayAbstract
The objective of the present investigation is focused on the anticancer activity of the ethanolic crude extract of Moringa concanensis leaf and bark against HepG2 cell line. The study was facilitated by collecting the plant sample and subjected to ethanol crude extraction. The anticancer activity of the crude extracted sample against HepG2 cell line was examined by MTT assay. The study confirms that the leaf crude extract of M. concanensis has pronounced anticancer potential against HepG2 cell lines while compared to that of the bark extract. The plant investigated possesses remarkable anticancer activity and hence isolation of the compound contributing to the activity may lead to develop at a novel and natural phytomedicine for the disease.
Downloads
375
165 Read
198
References
Alley MC, Scudiero DA, Shoemaker, RH, Paull KD, Monks A, Tierney S. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988; 48: 4827-33.
American Cancer Society. Cancer facts and figures. Atlanta, American Cancer Society, 2006.
Balamurugan V, Balakrishnan V. Evaluation of phytochemical, Pharmacognostical and antimicrobial activity from the bark of Moringa concanensis Nimmo. Int J Curr Microbiol App Sci. 2013a; 2: 117-25.
Balamurugan V, Balakrishnan V. Preliminary phytochemicals, pharmacognostic evaluation and antimicrobial activity of Moringa concanensis nimmo leaf. Global J Bio-Sci Biotechnol. 2013b; 2: 243-47.
Barnes S, Peterson TG, Coward L. Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer. J Cell Biochem. 1995; 22S: 181-87.
Bingham S, Riboli E. Diet and cancer: The European prospective investigation into cancer and nutrition. Nat Rev Cancer. 2004; 4: 206-15.
Bosch X, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999; 19: 271-85.
Bruce-Keller AJ, Begley JG, Fu W, Butterfield DA, Bredesen DE, Hutchins JB, Hensley K, Mattson MP. Bcl-2 protects isolated plasma and mitochondrial membranes against lipid peroxidation induced by hydrogen peroxide and amyloid b-peptide. J Neurochem. 1997; 70: 31-39.
Chung CP, Park JB, Bae KH. Pharmocological effects of methanolic extract from the root of Scutellaria baicalensis and its flavonoids on human gingival fibroblast. Planta Med. 1995; 61: 150-53.
Compton MM. A biochemical hallmark of apoptosis: Internucleosomal degradation of the genome. Cancer Met Rev. 1992; 11: 105-19.
Cummings MC, Winterford CM, Walker NI. Apoptosis. Am J Surg Pathol. 1997; 21: 88-101.
Earnshaw WC. Nuclear changes in apoptosis. Curr Opin Cell Biol. 1995; 7: 337-43.
Graham WC, Alistar DB. Pathogenesis of primary hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 1996; 8: 850-55.
Harborne JB. Arsenal for survival: Secondary plant products. Taxon 2000; 49: 435-49.
Ingram D, Sanders K, Kolybaba M, Lopez D. Case control study of phytooestrogens and breast cancer. Lancet 1997; 350: 990-94.
Jain SK. Ethnobotany in India: An overview. Howrah, India, BSI, 1983, pp 1-37.
Johnson PJ. The epidemiology of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 1996; 8: 845-49.
Kanzler S, Galle PR. Apoptosis in the liver. Cancer Biol. 2000; 10: 173-84.
Kerr JF. Shrinkage necrosis: A distinct mode of cellular death. J Pathol. 1971; 105: 13-20.
Kuo SM. Dietary flavonoid and cancer prevention: Evidence and potential mechanism. Crit Rev Oncogenesis. 1997, 8: 47-69.
Lahiri-Chatterjee M, Katiyar SK, Mohan RR, Agarwal R. A flavonoid anti-oxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res. 1999; 59: 622-32.
Lim HY, Lim YH, Cho YH, Lee CH. Induction of apoptosis in the HepG2 cells by HY53, a novel natural compound isolated from Bauhinia forficata. J Microbiol Biotechnol. 2006; 16: 1262-68.
Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol. 2006; 22: 248-53.
Messina MJ, Persky V, Setchell KDR, Barnes S. Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutr Cancer. 1994; 21: 113-31.
Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65: 55.
Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. 2003; 66: 1022-37.
Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S, Omata M. Combination therapy of intraarterial 5-fluorouracil and systemic interfere-on-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-97.
Okita K. Clinical aspects of hepatocellular carcinoma in Japan. Intern Med. 2006; 45: 229-33.
Pezzuto JM. Plant-derived anti-cancer agents. Biochem Pharmacol. 1997; 53: 121-33.
Seigler DS. Plant secondary metabolism, Kluwer Academic, Boston, 1998.
Shi YF, Sahai BM, Green DR. Cyclosporine A inhibits activation induced cell death in T-cell hybridomas and thymocytes, Nature 1989; 339: 625-29.
Srivastava. JK, Gupta S. Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells. Biochem Biophys Res Commun. 2006; 346: 447-53.
Tian Z, Pan RL, Si JY, Xiao PG. Cytotoxicity of cycloartane triterpenoids from aerial part of Cimicifuga foetida. Fitoterapia 2006; 77: 39-42.
Tong XH, Lin SG, Fujii M, Hou DX. Molecular mechanisms of echinocystic acid-induced apoptosis in HepG2 cells. Biochem Biophys Res Commun. 2004; 321: 539-46.
Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol. 1997; 139: 1281-92.
Yang CS, Landau JM, Huang MT, Newmark HL. Inhibition of carcinogenesis by dietary polyphenolic compounds. Ann Rev Nutr. 2001; 21: 381-406.
Zhong H, Tran LM, Stang JL. Induced-fit docking studies of the active and inactive states of protein tyrosine kinases. J Mol Graph Model. 2009; 28: 336-46.
Zhu AX. Hepatocellular carcinoma: Are we making progress? Cancer Invest. 2003; 21: 418-28.
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
